Regencell Bioscience Holdings Stock Current Valuation
| RGC Stock | USD 6.32 0.33 5.51% |
Valuation analysis of Regencell Bioscience helps investors to measure Regencell Bioscience's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to 8.06. The current year's Enterprise Value Multiple is expected to grow to 8.06. Fundamental drivers impacting Regencell Bioscience's valuation include:
Price Book 10.0066 | Enterprise Value 74.4 M | Enterprise Value Ebitda (44.58) |
Overvalued
Today
Please note that Regencell Bioscience's price fluctuation is very risky at this time. Calculation of the real value of Regencell Bioscience is based on 3 months time horizon. Increasing Regencell Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Regencell Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regencell Stock. However, Regencell Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.32 | Real 5.27 | Hype 6.32 | Naive 6.25 |
The real value of Regencell Stock, also known as its intrinsic value, is the underlying worth of Regencell Bioscience Company, which is reflected in its stock price. It is based on Regencell Bioscience's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Regencell Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Regencell Bioscience Holdings helps investors to forecast how Regencell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regencell Bioscience more accurately as focusing exclusively on Regencell Bioscience's fundamentals will not take into account other important factors: Regencell Bioscience Holdings Company Current Valuation Analysis
Regencell Bioscience's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Regencell Bioscience Current Valuation | 74.37 M |
Most of Regencell Bioscience's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regencell Bioscience Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Regencell Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Regencell Bioscience is extremely important. It helps to project a fair market value of Regencell Stock properly, considering its historical fundamentals such as Current Valuation. Since Regencell Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regencell Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regencell Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Regencell Current Valuation Historical Pattern
Today, most investors in Regencell Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Regencell Bioscience's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Regencell Bioscience current valuation as a starting point in their analysis.
Regencell Bioscience Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Regencell Bioscience Holdings has a Current Valuation of 74.37 M. This is 99.48% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.55% higher than that of the company.
Regencell Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regencell Bioscience's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regencell Bioscience could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics of similar companies.Regencell Bioscience is currently under evaluation in current valuation category among its peers.
Regencell Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regencell Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regencell Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Regencell Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 74.37 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Shares Owned By Insiders | 88.81 % | ||||
| Shares Owned By Institutions | 0.19 % | ||||
| Number Of Shares Shorted | 23.19 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 10.01 X | ||||
| EBITDA | (3.62 M) | ||||
| Net Income | (4.36 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 85.74 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (4 M) | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Price To Earnings To Growth | 2.15 X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.6 | ||||
| Market Capitalization | 82.24 M | ||||
| Total Asset | 8.44 M | ||||
| Retained Earnings | (21.62 M) | ||||
| Working Capital | 7.92 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
| Five Year Return | 4.37 % | ||||
| Net Asset | 8.44 M |
About Regencell Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regencell Bioscience Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regencell Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regencell Bioscience Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Regencell Bioscience Piotroski F Score and Regencell Bioscience Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.